One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists by Hirotaka Watada

Subjects: Get full text

GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks by Ioannis Ilias, Lina Zabuliene, Manfredi Rizzo

Subjects: “…glucagon-like peptide-1 receptor agonists…”
Get full text

Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence... by Jian‐Yu Jhu, Yu‐Wei Fang, Chung‐Yen Huang, Hung‐Hsiang Liou, Mon‐Ting Chen, Ming‐Hsien Tsai

Subjects: “…Glucagon‐like peptide‐1 receptor agonists…”
Get full text

Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review by Yao Wang, Jiangling Wang, Qian Gong, Haoming Wu, Shuhao Yang, Jufeng He, Xulin Hu, Tianfang Huang

Subjects: “…glucagon-like peptide-1 receptor agonists (glp-1ras)…”
Get full text

Managing cardiovascular events, hyperglycemia, and obesity in type 2 diabetes through microRNA regulation linked to glucagon-like peptide-1 receptor agonists by Xiaolei Miao, Maryam Davoudi, Zahra Alitotonchi, Ensieh Sadat Ahmadi, Fatemeh Amraee, Ashraf Alemi, Reza Afrisham

Subjects: Get full text

From Clinical Trial Evidence to Clinical Guidelines: Perspectives on REWIND from Clinicians in the Gulf and Levant Region by Talal Ashour, Sami Azar, Akram Echtay, Muhammad Farooqi, Tarek Fiad, Mohamed Hassanein, Ahmed Hassoun, Abdul Jabbar, Amin Jayyousi, Kari Ranta, Hani Sabbour, Fatih Tangi, Ibrahim Turfanda

Subjects: Get full text

Obstructive sleep apnea, the NLRP3 inflammasome and the potential effects of incretin therapies by Michelle Wei, Jennifer A. Teske, Jennifer A. Teske, Saif Mashaqi, Saif Mashaqi, Daniel Combs, Daniel Combs, Daniel Combs

Subjects: Get full text

Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus by Mijin Kim, Seung Chan Kim, Jinmi Kim, Bo Hyun Kim

Subjects: Get full text

Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA... by Sho Furusawa, Hiroshi Nomoto, Chiho Oba-Yamamoto, Jun Takeuchi, Miki Ito, Hiroyoshi Kurihara, Shin Aoki, Aika Miya, Hiraku Kameda, Akinobu Nakamura, Tatsuya Atsumi

Subjects: Get full text

Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease by Aaron King, Xi Tan, Neil Dhopeshwarkar, Rhonda Bohn, Katherine Dea, Charles E. Leonard, Adam de Havenon

Subjects: Get full text

Adverse effects of GLP – 1 Receptor Agonists by Anna Kasprzak, Monika Kułaga, Monika Grzybek, Diana Mazur-Lesińska, Barbara Szostak, Sylwia Wielgosz-Biała, Krzysztof Tyszkiewicz, Borys Łozowski, Małgorzata Kasprzak, Barbara Wilczyńska

Subjects: “…obesity, glucagon – like peptide – 1 receptor agonists…”
Get full text

Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta‐Analysis by Saixian Shi, Xiaofeng Li, Ye Chen, Jiahao Li, Yan Dai

Subjects: Get full text